Synthesis of steroid-oligonucleotide conjugates for a DNA site-encoded SPR immunosensor by Tort, Núria et al.
1 
 
“Synthesis of steroid-oligonucleotide conjugates for a site-encoded SPR immunosensor” 
Tort, N., Salvador, J.P., Aviñó, A., Eritja, R., Comelles, J., Martínez, E., Samitier, J., 
Marco, M.P. Bioconjugate Chem., 23(11) 2183-2191 (2012). doi: 10.1021/bc300138p 
 
Synthesis of steroid-oligonucleotide conjugates for a 
DNA site-encoded SPR immunosensor 
Nuria Tort1,5, J.-Pablo Salvador5,1, Anna Aviñó2,5,6, Ramón Eritja2,5,6,*, Jordi 
Comelles4,5, Elena Martínez4,5, Josep Samitier3,4,5, M.-Pilar Marco1,5 
1 Applied Molecular Receptors Group (AMRg) and 2 Nucleic Acids Chemistry Group. 
Chemical and Biomolecular Nanotechnology Department. IQAC-CSIC. 
Jordi Girona, 18-26, 08034-Barcelona, Spain 
3 Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), 
Balidri Reixac, 10-12, 08028 Barcelona, Spain 
4
 Department of Electronics, University of Barcelona, 
Martí i Franquès, 1, 08028 Barcelona, Spain 
5 CIBER de Bioingenieria, Biomateriales y Nanomedicina (CIBER-BBN) 
6 Institute for Research in Biomedicine, Baldiri Reixac 19, E-08028 Barcelona 
 
TITLE RUNNING HEAD. SPR Steroid-oligonucleotide conjugates 
*To whom correspondence should be addressed: phone 34-934039942 (email) 
recgma@cid.csic.es  
2 
 
ABSTRACT: The excellent self-assembling properties of DNA and the excellent 
specificity of the antibodies to detect analytes of small molecular weight under competitive 
conditions have been combined in this study. Three oligonucleotide sequences (N1up, N2up, 
and N3up) have been covalently attached to three steroidal haptens (8, hG and 13) of three 
Anabolic-Androgenic Steroids (AAS), stanozolol (ST), tetrahydrogestrinone (THG) and 
boldenone (B), respectively. The synthesis of steroid-oligonucleotide conjugates has been 
performed by the reaction of oligonucleotides carrying amino groups with carboxyl acid 
derivatives of steroidal haptens. Due to the chemical nature of the steroid derivatives two 
methods for coupling the haptens and the ssDNA have been studied: a solid-phase coupling 
strategy and a solution-phase coupling strategy. Specific antibodies against ST, THG and 
B have been used in this study to asses the possibility of using the self-assembling 
properties of the DNA to prepare biofunctional SPR gold chips based on the 
immobilization of haptens, by hybridization with the complementary oligonucleotide 
strands possessing SH groups previously immobilized. The capture of the steroid-
oligonucleotide conjugates and subsequent binding of the specific antibodies can be 
monitored on the sensogram due to variations produced on the refractive index on top of 
the gold chip. The resulting steroid-oligonucleotide conjugates retain the hybridization and 
specific binding properties of oligonucleotides and haptens as demonstrated by thermal 
denaturation experiments and surface plasmon resonance (SPR). 
 
KEYWORDS: Anabolic-Androgenic Steroids (AAS), steroid-oligonucleotide conjugate, 
DNA-directed immobilization (DDI), Surface Plasmon Resonance (SPR) 
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INTRODUCTION 
The food safety, biomedical research and environmental monitoring areas require methods 
of screening with the ability to detect, rapidly and sensitively, trace amount of small targets 
(<1000 Da). As an example, Anabolic Androgenic Steroids (AAS) are completely 
prohibited substances by the WADA (World Antidoping Agency) (1) and the European 
Community (2), for their respective use to improve athletic performance and to increase 
meat production in the agro-alimentary field, due to the associated adverse health effects. 
Immunosensors based on the surface plasmon resonance (SPR) principle provide a rapid 
and convenient analytical alternative for monitoring (bio)chemical substances in a label-
free way (3-9). Several strategies have been used to anchor the immunoreagents onto gold 
chips to develop SPR biosensors to detect small molecules under competitive 
immunochemical configurations. In indirect formats, usually a protein functionalized with 
the hapten is immobilized on the surface of the transducer (10-12) however; alternative 
methods to avoid the use of a carrier protein have been described. For example, an 
oligo(ethyleneglycol) (OEG) linker was used on a SPR biosensor to detect 2,4,6-
trinitrotoluene (TNT) (13) and testosterone (14). In direct detection formats, the antibody 
can be immobilized directly through a self-assembled layer (SAM) of heterobifunctional 
linkers possessing a thiol group, although alternative methods to appropriately orientate the 
antibody molecule have also been described. Thus, it has been reported the immobilization 
of antibodies by affinity interaction with a layer of protein A previously immobilized on the 
gold substrate (15). Moreover, the use of DNA–protein conjugates has also been reported 
on nanoscale immunosensors microstructured biochips (16). Hence, a protein G-DNA 
conjugate has been employed to ensure controlled immobilization of antibodies to intended 
areas of a chip surface or to particles (17). The DNA-directed immobilization (DDI) 
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strategy provides a chemically mild process for the simultaneous binding of multiple 
proteins to a solid support using DNA surfaces as immobilization matrices. It consists on 
tagging biomolecules with oligonucleotides chains that are complementary to ssDNA 
previously linked on the surface. An additional advantage of this strategy is the possibility 
to produce regenerable sensor surfaces due to the reversible nature of the DNA 
hybridization reaction. This strategy has been used to immobilize antibodies covalently 
linked to ssDNA onto a SPR surface where the complementary strands have been 
previously immobilized, to detect three fertility hormones in a direct competitive format 
(18, 19). However, this approach has been rarely used to immobilize haptens on a SPR gold 
chip. Previously, we have demonstrated the possibility to use DDI to create hapten 
microarrays for fluorescent detection (20). This time, our objective has been to demonstrate 
the biofunctionality of steroid-oligonucleotide bioconjugates synthesized and characterized 
to use them on a SPR biosensor and to assess the possibility to develop multiplexed SPR 
immunosensors for small organic molecules by directly immobilizing the haptens on the 
gold chip through a DDI approach (12, 22-27). 
 
EXPERIMENTAL PROCEDURES 
Chemicals, reagents and buffers  
General. Phosphoramidites and ancillary reagents used during oligonucleotide synthesis 
were from Applied Biosystems (PE Biosystems Hispania S.A., Spain), Link Technologies 
(Link Technologies Ltd., Scotland) and Glen Research (Glen Research Inc., USA). The rest 
of the chemicals were purchased from Aldrich, Sigma or Fluka (Sigma-Aldrich Química 
S.A., Spain). NAP-10 columns (Sephadex G-25) were purchased from Pharmacia Biotech. 
The preparation of the stanozolol (ST), tetrahydrogestrinone (THG) and boldenone (B) 
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haptens (8, hG and 13, respectively) and the production of the antiserums (As147, As170 
and As138, respectively) has been described previously (28-30). N,N’-
dicyclohexylcarbodiimide 99% (DCC) was purchased from Aldrich and the N-
hydroxysuccinimide (NHS) from Fluka. Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) was from Bachem (Bachem, Switzerland). Long chain 
alkylamine Controlled Pore Glass (LCAA-CPG) was from CPG (CPG Inc., New Jersey, 
USA). 
 
Instrumentation  
Oligonucleotide sequences were synthesized on an Applied Biosystems DNA synthesizer 
model 3400 (Applied Biosystems, USA). Mass spectra (matrix-assisted laser desorption 
ionization time-of-flight, MALDI-TOF) were provided by the Mass Spectrometry service 
of the University of Barcelona. UV-Visible spectra were recorded on a Shimadzu UV-
2101PC spectrophotometer. HPLC (SHIMADZU-9A) with manual injector volume of 150 
µL, bomb LC-9A and detector SPD-M6A UV-VIS.  
Commercial SPR chips with bare gold surface, SPRchip™ and spotReady™ (GWC 
Technologies, USA) substrates, were used for all the experiments. Imaging SPR 
measurements were collected with a GWC Technologies SPR Imager II instrument (GWC 
Technologies, USA). Measurements were performed at a fixed angle of incidence 
collecting the changes on the reflected light intensity through imaging the SPR chip with a 
CCD camera. The spotReady™ chips contain an array of gold spots where positive and 
negative controls can be included and measured simultaneously. Individual chips were 
index-matched to the prism and fitted with a 20 µl flow cell connected to a peristaltic pump 
from Ismatec (Glattbrugg, Switzerland). A total volume of 0.5 mL was needed to 
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completely fill the tubing and flow cell with buffer or analyte. The SPR images were 
collected and analyzed using V++ software (Digital Optics, New Zeland). 
 
Synthesis and purification of oligonucleotides and steroid-oligonucleotide conjugates 
Three pairs of oligonucleotide complementary sequences were designed (see Table 1). 
Three oligonucleotides were prepared with an amino group at the 5’-end (N1up, N2up and 
N3up) and the three complementary sequences contained a thiol group at 5’-end (N1down, 
N2down and N3down). Oligonucleotide sequences carrying an amino and thiol group at the 
5’-end were assembled on a 1 µmol scale. The benzoyl (Bz) group was used for the 
protection of the amino group of C and A, and the isobutyryl (ibu) group for the protection 
of G. The phosphoramidite derivative of 6-aminohexanol carrying the monomethoxytrityl 
(MMT) group (Glen Research and Link Technologies) (31) was used for the introduction of 
the amino group at the 5’-end. The thiol group at the 5’-end was introduced using the 
phosphoramidite derivative of 6-hydroxyhexyldisulfide protected with the dimethoxytrityl 
(DMT) group (5' thiol modifier C6 S-S CE phosphoramidite, Link Technologies, Inc., 
Scotland). Coupling yields were >98%. After the assembly of the sequences, the resulting 
solid supports (except for N1up and N2up) were treated with concentrated ammonia for 6 h 
at 50ºC. Oligonucleotides carrying thiol groups were deprotected with concentrated 
ammonia carrying 0.1M dithiotreitol (DTT). The resulting N1-3down-SH oligonucletides 
were stored in presence of DTT to prevent the disulfide formation. Prior to immobilization 
thiol-oligonucleotides were desalted with Sephadex G-25 (NAP-10 columns, GE 
Healthcare) eluted with water to remove the excess of DTT. 
The corresponding N1-3up-NH2 oligonucleotides have been conjugated with the steroids (8, 
hG and 13, respectively). For the preparation of these conjugates we have used two 
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different approaches: 1) the active ester method in aqueous solution (solution-phase 
strategy), which consists on the activation of the acid of the steroidal haptens using DCC 
and NHS, and 2) the solid-phase strategy, using PyBOP as activating agent and 
diisopropylethylamine (DIPEA). 
 
1) Synthesis of oligonucleotides carrying steroids using the solution-phase coupling 
protocol  
The resulting solid support obtained after the assembly of the oligonucleotide sequence 
(N3up-NH2), and removal of the last MMT group, was treated with concentrated ammonia 
for 6 h at 50ºC. The mixture was filtered and the ammonia solution concentrated to dryness. 
The residue was passed over a Dowex 50x4 (Na+ form) column to exchange ammonium for 
sodium ions. The resulting amino-oligonucleotide was dissolved in 0.2 mL of water, and 
mixed with 0.1 mL of an aqueous buffer. We tried three different aqueous buffers: 1) 1 M 
sodium carbonate, pH 9.0; 2) 50 mM Tris pH 8.5 and 3) 0.2 M sodium borate pH 8.6.  In a 
separate container the steroidal hapten with the carboxylic acid group (13, 10 molar excess) 
was dissolved in 0.1 mL of DMF and mixed with NHS (25 molar excess) and DCC (50 
molar excess). The mixture was left with magnetic stirring for 3 h at room temperature, 
until the solution became opaque due to the precipitation of the urea. Then, we centrifuge 
(10.000 rpm for 15 min) to remove the precipitate and the supernatant was added to the 
aqueous solution of the amino-oligonucleotide. The reaction mixture was kept at 37ºC with 
magnetic stirring overnight. The mixture was concentrated to dryness and the residue was 
dissolved in water and passed through a NAP-10 column. Finally, the oligonucleotide 
fractions were analyzed by reverse-phase HPLC-UV. HPLC solutions were solvent A: 5% 
ACN in 100mM triethylammonium acetate (TEAA) pH 6.5 and solvent B: 70% ACN in 
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100 mM triethylammonium acetate pH 6.5. Column: PRP-1 (Hamilton), 350 x 8 mm. Flow 
rate: 3 mL/min. A 20 min lineal gradient from 5-35% ACN was used. The desired 
oligonucleotide conjugate carrying the steroid eluted at around 11 min, while the unreacted 
amino-oligonucleotide eluted at around 2-5 min. The desired product was characterized by 
UV-spectra and mass spectrometry (MALDI-TOF), with a global yield for 13-N3up of 20 
(carbonate buffer) -30% (Tris, borate buffers). MALDI-TOF m/z (negative mode) 13-N3up, 
calc 6639, found 6400 (M-239) corresponding to the fragmentation of the ester linkage of 
the hapten during the acquisition of MALDI spectra. Electrospray m/z (negative mode) 13-
N3up, calc 6639, found 6639. Increasing the molar excess of active ester from 10 to 30 
times excess, allows the conversion of the amino-oligonucleotide to the desired conjugate 
to 45%.   
 
2) Synthesis of oligonucleotides carrying steroids using the solid-phase coupling protocol 
The oligonucleotide sequences carrying an amino group at the 5’-end were prepared as 
described above (N1,2up-NH2). The resulting solid supports were treated with 3% 
trichloroacetic acid/CH2Cl2 to eliminate the MMT group, washed with ACN and reacted 
with the carboxylic acid derivatives of the steroids as follows. A mixture containing 10 
molar excess of the hapten (hG or 8), 20 molar excess of N,N-diisopropylethylamine 
(DIEA) and 10 molar excess of PyBOP was prepared in dry DMF (0.2 mL). The mixture 
was left for 10 min at room temperature and added to the support. After 30 min at room 
temperature, the mixture was filtered and washed with DMF and ACN. The support was 
dried and concentrated ammonia (1 mL) was added. The ammonia solution was left for 6 h 
at 50 ºC. The mixture was filtered and the ammonia solution was concentrated to dryness. 
The fractions containing oligonucleotide were analyzed by HPLC-UV as described above. 
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The desired steroid-oligonucleotide conjugates eluted at around 11 min, and were obtained 
with global yields of 52% for 8-N1up and 40% for hG-N2up. Finally, the conjugates were 
characterized by UV and mass spectrometry (MALDI-TOF). MALDI-TOF m/z (negative 
mode) 8-N1up, calc 6668, found 6672; hG-N2up, calc 6619, found 6614. In this last 
compound we also observed a second peak at 6333 m/z corresponding to the hapten 
fragmentation at the oxime bond. 
 
DNA site-encoded SPR immunosensor 
General considerations. All the SPR experiments began with a buffer baseline (10mM 
PBS with 100 mM NaCl, assay buffer) and the same buffer was used to wash between each 
step and to prepare all the solutions of the bioreagents. All the solutions were flowed at a 
rate of 3 µL·s-1. Solutions carrying the thiolated oligonucleotides (N1,2,3 down-SH) and the 
steroid-oligonucleotide conjugates (8-N1up, hG-N2up and 13-N3up) were prepared at 150 
µg·mL-1 and 60 µg·mL-1, respectively in the assay buffer. Nonspecific adsorption of 
proteins was avoided by using a blocking solution of 2% of bovine serum albumine (BSA). 
Antisera for ST (As147), THG (As170), B (As138) and for negative controls (CTR-NEG, 
pre-immune serum) were diluted 250 times in the assay buffer.  
Individual SPR procedure. (see  
Figure 1, A) Biofunctionalization of the SPRchip™ was accomplished by flowing a solution 
of the thiolated oligonucleotides down (N1,2,3down-SH) for 15 min. A solution containing 
the corresponding steroid-oligonucleotide conjugate (8-N1up/ hG-N2up/ 13-N3up) in the 
assay buffer was flowed to the cell for about 20 min, until a steady-state situation. 
Following the chip was washed (10 min) and the blocking solution was passed (15 min). 
After a new washing step, the solution of the specific antisera (As147/ As170/ As138, 
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1/250 dilution) was flowed for about 20 min until the signal reached the maximum, and 
washed again with the assay buffer. At the end of the cycle, the chips were regenerated by 
flowing a solution of 0.3M NaOH for about 15 min. The regeneration step provided gold 
chips with the Nxdown-SH oligonucleotides immobilized. Absence of nonspecific binding 
was assessed by passing a solution of a pre-immune serum. 
Multiplexed SPR procedure. (see  
Figure 1, B) For this experiment a spotReady™ substrate with 16 gold spots per chip, with 
a spot diameter of 1 mm, was used and the solutions of Nxdown-SH oligonucleotides (150 
µg·mL-1 in the assay buffer) were deposited (0.5 µL/spot) per triplicate for 1 hour at room 
temperature. Then, with the chip inside the SPR set up, a solution containing a mixture of 
the three steroid-oligonucleotide conjugates (8-N1up/ hG-N2up/ 13-N3up) was flowed to the 
cell for about 20 min, until a steady-state situation. Following the chip was washed (10 
min) and the blocking solution was passed (10 min). After a new washing step, a solution 
with a mixture of the three specific antisera (As147/ As170/ As138, called cocktail As), was 
flowed for about 25 min until the signal reached the maximum, and washed again with 
buffer. The existence of no cross-hybridization between the different oligonucleotides pairs 
and the affinity of each antibody for the different steroid-oligonucleotide conjugates were 
previously studied (20). 
 
RESULTS AND DISCUSSION 
Synthesis and purification of steroid-oligonucleotide conjugates  
A set of three complementary pairs of ssDNA (N1, N2 and N3, up and down) were 
synthesized. These sequences have 50% G:C content (purines/pyrimidines) and have the 
same composition but different sequence. In this way it is expected that the three resulting 
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duplexes will have similar hybridization properties. The sequences should display high 
hybridization efficiency for maximum hapten density at the surface after the 
immobilization. The specificity of the hybridization of these sequences has been previously 
studied in our group in a microarray multiplexed competitive format (20) and the results 
indicated hardly any cross-hybridization between the three sequences. 
Once a complete set of oligonucleotides sequences were chosen, the steroid-oligonucleotide 
conjugates were prepared. The synthesis of oligonucleotides carrying steroids such as 
cholesterol (32, 33), hydroxyprogesterone (34), dexamethasone (35), digoxigenin (36), 
cholic (37), lithocholic (38) and bile acids (39) have been described in order to obtain 
hydrophobic derivatives of oligonucleotides for antisense, triplex and RNA interference 
studies (40). Most of these compounds are synthesized by conjugation of carboxylic acid 
derivatives to oligonucleotide carrying amino groups although the direct incorporation to 
oligonucleotides using the corresponding phosphoramidites have also been described for 
compounds that can be prepared in large amounts (32-34). In our case the amount of 
carboxylic acid derivatives available was low so post-synthetic methods were selected. 
Thus, ST, THG and B steroid-oligonucleotides conjugates were prepared through the 
formation of amide bonds (see Table 1). The steroidal haptens used in these conjugations 
have been previously used to develop enzyme linked immunosorbent assays (ELISAs) to 
detect AAS in real samples (28-30). 
The conjugation of boldenone hapten (13) to amino-oligonucleotide N3up was performed 
with the unprotected amino-oligonucleotide in aqueous solution. The hapten 13 has an ester 
group which in basic medium could be hydrolyzed. For this reason conjugation was not 
possible before ammonia deprotection. Therefore, we used the solution-phase coupling to 
obtain the desired conjugate 13-N3up (B) in 20-30% yield (Figure S2, supporting 
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information). The NHS-ester of 13 was prepared by reaction of the carboxylate moiety with 
NHS using DCC (41). Increasing the molar excess of active ester from 10 to 30 times 
excess, allows the conversion of the amino-oligonucleotide to the desired conjugate to 45% 
(Figure S2, supporting information).. The mass obtained for this conjugated was 6400 m/z 
while the mass expected was 6639 m/z. We attribute this difference at the fact that during 
MALDI-TOF analysis fragmentation can occur as a result of heating (laser ionization) in 
the acidic environment (the matrix) and then what we could observe is the oligonucleotide 
with the steroid attached hydrolyzed at the ester point. This was confirmed by using 
electrospray MS analysis. The softer ionization conditions provided the expected mass (13-
N3up, calc 6639, found 6639). 
On the other hand, it had been also reported that solid phase synthesis may be advantageous 
to the standard synthesis in solution (42) since it allows forming the amide bond in organic 
solvent in which the steroidal haptens have better solubility. Thus, the conjugates 8-N1up 
(ST) and hG-N2up (THG) (Table 1) were obtained in higher yields (52-40%), 
demonstrating that the conjugation reaction is clearly advantageous using the solid-phase 
coupling protocol. Both conjugates were characterized with MALDI-TOF mass 
spectrometry (8-N1up, calc 6668, found 6672; hG-N2up, calc 6619, found 6614).  
In order to assess the influence of the steroids in the duplex structure denaturation curves 
were analyzed. Table S1 (supplementary information) shows the melting temperatures of 
duplexes carrying the steroids stanozolol (8), tetrahydrogestrinone (hG), and boldenone 
(13). As expected, the presence of the steroid at the 5’-end of the duplex has very little 
effect in the stability of the duplex. 
The recognition of the oligonucleotide-steroid conjugates by specific antibodies was 
analyzed by immobilization of the duplex DNA carrying steroids on glass surfaces 
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followed by incubation with the specific antisera and the visualization of the antigen-
antibody interaction with a fluorescently labeled anti-rabbit secondary antibody as 
described previously [20]. The presence of the oligonucleotides chain does not affect to the 
recognition of antigen antibody as it can be observed in the detectability parameters (LOD 
and IC50) in the table S2 in the supplementary material.  
 
Evaluation by SPR of the biofunctionality of the steroid-oligonucleotide conjugates 
Hybridization. The specificity of the hybridization step was assessed by SPR by flowing 
the solutions of the steroid-N1-3up conjugates into a cell containing the N1-3down 
functionalized chips and recording the SPR signal (see Figure 2). The DNA double helix is 
stabilized by hydrogen bonds between the bases of the two strands. The strength of the 
double-stranded formation depends on a) the number of matching bases in a sequence, b) 
the number and loci of mismatches and c) the base composition. The prevailing DNA 
architecture, the double helix, has well stacked nearly parallel bases with overlapping π-
electron systems. Such π-electron systems may be good candidates for long-distance and 
one-dimensional (linear) charge transport (43). Yoo et al. (44, 45) demonstrated differences 
in conductivity due to variation in the base pair sequence. Poly(dG).Poly(dC) showed a 
conductivity of 40 S/cm, whereas that for Poly(dA).Poly(dT) was about 0.1 S/cm. This fact 
could be an explanation to the different behavior in the hybridization between the three 
hapten-oligonucleotide conjugates, because as it can be observed in Figure 2, 
N1down/N1up-8 pair has a lower change in the SPR signal than N2down/N2up-hG and 
N3down/N3up-13 pairs. In Table 1, it can be observed that the sequence of the 
oligonucleotide N1down at the 5’-end has CAG whereas in the sequences N2down and 
N3down, in both cases we have CGG. Therefore, changes in the conductimetric properties 
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of the double helix, could affect the refractive index and influence in the SPR signal (46, 
47). 
 
Immunochemical recognition. Three specific antisera (As147, As170 and As138, 1/250 
dilution) and a non-specific serum (CTR-NEG) were used to test if after the conjugation of 
the steroids with the oligonucleotides chains, the antibodies could still recognize their 
corresponding steroidal haptens. The features of these antibodies have been previously 
described (28-30). Results presented in the Figure 3 and Figure S1 (supporting 
information), show the change in the SPR signal recorded as result of three consecutive 
cycles in different chips for each system (ST, THG and B). The first cycle, shows the 
specific antibody binding to each steroid-oligonucleotide conjugate (steroid-N1-3up) 
hybridized on the surface of the sensor. On each graph it can also be observed the absence 
of nonspecific signal when the CTR-NEG serum was injected, after regenerating the 
surface. Similarly, subsequent injection of the specific antiserum on systems ST and THG 
allows recovering again the same signal. In the case of B system the signal of the third 
cycle is lower than the signal obtained of the first cycle, but both first and third cycle are 
clearly much higher than the non-specific (CTR-NEG) second cycle. The difference 
between the first and the third cycle for the B system (N3down-N3-up-13/As138) could be 
attributed to the low S/N ratio obtained or to a small lost of the binding response. The 
differences observed in the maximum of the signal and in the slope of the binding step, 
between the three systems N1, N2, N3 (see Figure 3) is due to the distinct antisera affinity for 
the corresponding steroid-oligonucleotide conjugates. And another remarkable fact is the 
complete regeneration of the surface with a simple washing step with diluted NaOH 
solution, which offers to these chips the possibility to be reused.  
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Finally, as a proof of concept, the possibility to develop a multiplexed SPR immunosensor 
was demonstrated. In this experiment the DNA-directed immobilization of a cocktail of 
steroid-oligonucleotide conjugates was used to detect the three AAS simultaneously, under 
competitive conditions (see Figure 4). The DNA biofunctionalized chip was prepared using 
a spotReady™ substrate with 16 gold spots per chip in which the oligonucleotides N1down-
SH, N2down-SH and N3down-SH were deposited per triplicate spots. Then, with the chip 
placed inside the SPR set up, the assay was performed as described in the experimental 
section by flowing a solution containing a mixture of the three steroid-oligonucleotide 
conjugates (8-N1up/ hG-N2up/ 13-N3up) (Figure 4 left), followed by the cocktail As (Figure 
4 right). As it can be observed the change in the refractive index produced on the 
hybridization step and as result of the antibody binding is recorded as an SPR signal on 
each respective spot demonstrating the possibility of using DDI to prepare hapten-
biofunctionalized SPR chips responding simultaneously to the presence of the 
corresponding specific antibodies.  
 
 
CONCLUSIONS 
Immunochemical methods show great potential for detection of small targets for a large 
number of applications. In spite of the powerful analytical tools that are being developed, 
one of the important issues is the efficient immobilization of analytes to the sensing 
sufaces. The present work demonstrates the potential of oligonucleotide-steroid conjugates 
for DNA-directed immobilization of haptens on sensor surfaces. To this end, we have 
demonstrated that three different steroids can be conjugated to oligonucleotides using the 
same steroid derivatives used for the obtention of protein-conjugates needed for 
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immunization. Moreover, the results show that coupling of the hapten to the 
oligonucleotides preserves the antibody recognition properties allowing the construction of 
a biosensor for the specific detection of steroids. The presence of the steroid do not affect 
the hybridization properties of the  oligonucleotides. The immobilization of the conjugates 
to the gold sensing surface is performed by immobilization of the complementary strand 
carrying a thiol group followed by hybridization.  The DNA-directed immobilization 
strategy presents the advantage of the possibility to re-use the same sensor chip for multiple 
measurements after an easy dehybridization step. Moreover, consecutive measurement 
cycles addressed to detect other molecules could be performed on the same DNA-chip, by 
just binding distinct haptens, proteins, or antibodies, to the complementary oligonucleotides 
strands. The strategy presented here shows a valuable approach for small organic molecule 
detection on biosensors. It has been demonstrated the coupling of the hapten to the 
oligonucleotide preserves the antibody recognition properties allowing the construction of a 
biosensor for the specific detection of esteroids. For these reasons, the use of the DNA-
direct immobilization strategy opens the way to get a multiplexed imaging SPR 
immunosensor by easily immobilizing distinct haptens on different spots of the ssDNA 
biofunctionalized chip. This methodology opens the possibility to detect a large number of 
analytes simultaneously using a DNA site-encoded chip in multichannel SPR devices (12, 
22) and SPR-imaging biosensors (23-27), or in a future, using also encoded nanoparticles 
biofunctionalized with the specific antibodies for multiplexes localized surface plasmon 
resonance (LSPR) sensing. Finally, the methodology described for the preparation of the 
steroid-oligonucleotide conjugates may be useful for the generation of potential nucleic 
acids drugs. 
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Table 1: Oligonucleotides sequences and chemical structures of the steroidal haptens used 
in this study. 
Name Sequence 
N1down-SH 5' HS-(CH2)6-CAGGACAATATCGTTGCGTG 3' 
 
8-N1up 
N
N
O
HO
NH-(CH2)6-CACGCAACGATATTGTCCTG 3'
4
 
N2down-SH 5' HS-(CH2)6-CGGAGGTACATTCGACTTGA 3' 
 
hG-N2up 
HO
N
O
O
NH-(CH2)6-TCAAGTCGAATGTACCTCCG 3' 
 
N3down-SH 5' HS-(CH2)6-CGGATAGAGCACTACGTTGT 3' 
 
13-N3up 
O
O
O
NH-(CH2)6-ACAACGTAGTGCTCTATCCG 3'
O
3
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Scheme 1: Synthesis of steroid-oligonucleotide conjugates where a) ammonia treatment, b) 
hapten coupling using DCC and NHS and c) hapten coupling using PyBOP and DIPEA. 
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Figure 1: Schematic representation of the experimental procedure employed to assess the 
steroid-oligonucleotide bioconjugate biofunctionality by SPR. ssDNA biofunctionalized 
chips are used to immobilize the haptens through hybridization with the corresponding 
steroid-oligonucleotide bioconjugates. Subsequently, biofunctionality is assessed by 
exposing the chips to specific antibodies. A) Evaluation of the biofunctionality of each 
steroid-oligonucleotide conjugate (8-N1up, hG-N2up and 13-N3up) using the individual 
SPR procedure. B) Evaluation of the DNA site-encoded applicability of these conjugates 
for the development of a multiplexed SPR immunosensor. 
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Figure 2: SPR sensograms recorded on the hybridization step between the steroid-
oligonucleotide conjugates and the oligonucleotides down previously immobilized on the 
chip surface. 
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Figure 3: SPR sensograms recorded on the antibody binding step: ST (top), THG (middle) 
and B (bottom). Each graph shows the response of three consecutive cycles, after 
regeneration of the surface at the end of each cycle: a) first cycle: specific antibody; b) 
second cycle: preimmune serum; c) third cycle: specific antibody. 
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Figure 4: Sensograms recorded in the DNA-directed SPR immunosensor; on the left, the 
specific hybridization of the steroid-oligonucleotide conjugates with their complementary 
strands previously immobilized on the gold chip; on the right, the immunochemical 
recognition of each specific antibody for the corresponding steroid. 
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